Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

The long-standing practice of adding fluoride to community drinking water in the United States is now under sharp review as questions rise about whether its advantages continue to outweigh possible risks. A fresh set of findings pushes back against recent warnings about fluoride in water and suggests that it might offer added benefits.

This renewed national discussion began after a government report from the National Toxicology Program stated that high fluoride exposure was tied to lower IQ in children. That report, however, assessed fluoride amounts that were at least twice higher than federal recommendations and had limited information about what happens at lower, commonly used levels, as per CNN.

However, the latest study examined fluoride quantities that match the usual suggested range in drinking water. Researchers found strong evidence showing that children who grew up with water containing these lower levels of fluoride performed better on cognitive assessments than those who had no fluoride exposure.

Fluoride in US Public Water Faces Renewed Questions

Dr. Rob Warren, lead author of the study released in Science Advances, said he was surprised by the National Toxicology Program’s earlier conclusions and felt the need to produce evidence more suitable for public policy. He explained that he pursued the work because it was a major question without a clear answer.

The national debate has also intensified as US Department of Health and Human Services Secretary Robert F. Kennedy Jr. has labeled fluoride an industrial waste and pointed to possible IQ loss while calling for a rollback of federal guidance. Utah and Florida have already moved to prohibit fluoridation of public water.

As per CNN, Warren compared the situation to testing a heart medication. If the advised dose is 100 milligrams, but a study measures reactions to nearly a million milligrams, the results do not reflect what happens at the normal dose. He said that this is how much of the fluoride research has been structured and that only extremely high doses have shown harmful effects, which is not helpful for policy decisions.

Warren directs a long-running program that began in the US Department of Education and has followed tens of thousands of Americans from their high school years in the 1980s through several decades.

Fluoride and Cognition: What The Study Found

For the current analysis, the team linked math, reading and vocabulary test scores from nearly 27,000 participants to the level of fluoride in their childhood drinking water. These measurements were based on older records from the US Geological Survey and the Department of Health and Human Services, as per CNN.

Researchers worked under the assumption that participants spent their entire upbringing near their high schools. They sorted people into three groups. One group had steady exposure to recommended fluoride levels either through natural sources or public water treatment. Another group never had fluoride in their water. A third group had mixed exposure because their community changed its water policy at some point.

Students who had fluoride for only part of their childhood scored higher on tests than peers who never had it. Those who grew up with fluoride throughout all their childhood years scored even better. Follow-up testing that continued up to 2021, when many had reached about 60 years of age, also showed no sign that fluoride contributed to cognitive decline.

Warren clarified that cognitive tests are not exact IQ scores, although they relate strongly. Test results reflect both mental ability and the learning opportunities a person receives. He is currently working on a follow-up project that will look more closely at fluoride and IQ with improved childhood location data.

Other studies this year suggested that removing fluoride from public water in the United States could lead to more than 25 million extra cavities among children and teenagers in five years along with nearly 10 billion dollars in dental treatment costs. Although the new study did not measure dental health, experts noted that pain from untreated cavities can interfere with a child’s ability to attend school or stay focused, which may influence academic scores.

Why Experts Still Differ on Fluoride Policy

Fluoride occurs naturally in some groundwater and foods. It protects teeth by strengthening enamel, which can be damaged by acids formed from bacteria, plaque and sugar. Communities in the United States started adding fluoride to water systems in 1945 to improve oral health in a cost-effective way.

The American Dental Association and numerous specialists continue to support community water fluoridation. The US Centers for Disease Control and Prevention has also kept its recommendations unchanged. The agency does not have authority to require fluoridation, but it considers 0.7 milligrams per liter the ideal amount.

Recently, the US Food and Drug Administration restricted the use of prescription fluoride supplements. The agency noted that unapproved fluoride products may alter the gut microbiome and that better options exist to protect teeth.

In a written response published with the new research, Dr. David Savitz from Brown University argued that before ending a decades-long public health practice, there must be clear proof of harm at commonly used fluoride levels. He wrote that there is still no convincing evidence that fluoridation lacks benefit or causes damage at recommended doses.

He quoted a well-known saying, noting that if something is not broken, there is no reason to fix it. He said the new study suggests that fluoridated water remains on the side of being effective and safe.

The Neuralink chip is a piece of technology that’s hoped will one day allow people to operate devices like phones and computers using their thoughts. Its creator, tech mogul Elon Musk, describes it as a “Fitbit in your skull with tiny wires.” Elon Musk's brain implant company Neuralink said recently that 12 people worldwide have received its chips. The device is meant to have several applications, from restoring motor functionality within people to enabling a brain-computer interface. The question now is whether it will be able to reverse paralysis in the future or not.

Neuralink: What Is Neuralink, And What Does It Do?

Neuralink is a neurotechnology company Musk set up in 2016. The device is roughly the size of a coin and is implanted into the skull, with hair-thin threads placed inside specific parts of the brain to form a working brain-computer interface.

The implant records brain signals and transfers them to an external device, such as a smartphone, through Bluetooth. Its first product, Telepathy, is designed to let a person operate their phone or computer through intention alone. By placing the chip in regions that manage movement, Neuralink believes it could help people living with neurological conditions. Musk has said that early users would likely be people who cannot use their limbs.

Neuralink: What Testing Has Neuralink Carried Out In The Past?

As per Reuters, the company has run trials using monkeys and pigs. Demonstrations have featured monkeys moving a cursor or playing simple on-screen games using the implant. Neuralink maintains that no monkey died because of the device itself, though reports have circulated describing complications in some animals, including paralysis, seizures and swelling in the brain.

Neuralink: Can Neuralink Cure Paralysis?

The human brain contains millions of neurons responsible for movement, emotion and thought. These neurons send electrical signals down pathways that run from the brain to the rest of the body. If a person tries to stand up, the brain sends electrical instructions to the legs, and the reaction is instant. Paralysis develops when pathways in the spinal cord are damaged or blocked, according to the description on Neuralink’s website.

Because the Neuralink implant reads the brain’s signals, it can forward those signals to the limbs even when the spinal cord no longer relays them. This would require one implant in the brain and another placed below the injured area of the spinal cord. With steady training, a person could regain movement, raising the possibility that Neuralink may one day help restore mobility.

Neuralink Ethical Concerns

Experts have questioned the company’s experiments on animals and the general risks linked to brain operations, which can include seizures or bleeding. They have also pointed to worries about data privacy and long-term surveillance, since there is limited detail on how much control users will have over their neural information.

Earlier this year, the US Department of Transportation fined the company for failing to register as a carrier of hazardous biological material, including implants removed from primates, according to agency records reviewed by Reuters.

Neuralink Is FDA Approved

In late May 2023, the FDA granted Neuralink permission to start human testing. The company said on Twitter that the approval marked the beginning of its first clinical study in people, calling it a vital step toward making the technology accessible in the future.

Neuralink has continued to share updates, and in July 2025, it announced that it had completed two brain-implant procedures on the same day. Both individuals are said to be recovering well. Musk responded soon after, expressing confidence in what the technology might achieve in the coming years.

A newly mutated version of the familiar flu virus, Influenza H3N2, known as subclade K, is moving quickly across the northern hemisphere. This rise has raised concerns that the United States may be facing a tougher flu season. This specific offshoot of influenza has become the leading strain in several countries, including the US, Japan, the UK and Canada.

In the Southern Hemisphere, H1N1 led most of the flu activity this year, and H3N2 subclade K only began to spread near the end. Early figures from the UK and Japan show that about 90 percent of flu samples were linked to H3N2 subclade K, according to a report from the University of Minnesota. With a fresh variant circulating and fewer Americans choosing to get vaccinated, the coming months could be quite challenging.

Where Has The H3N2 Subclade K Strain Been Detected?

The European Centre for Disease Prevention and Control reports that this strain has appeared across all continents and makes up roughly one third of all A (H3N2) sequences submitted to the Global Initiative on Sharing All Influenza Data between May and November 2025 worldwide, and nearly half in the European Union. The agency notes that clear data on how well the current vaccine performs in real-world conditions remains limited. Even so, existing vaccines are still expected to help protect against serious illness.

The possibility of a flu season led mainly by H3N2 subclade K is considered moderate, based on the agency’s assessment. The threat is higher for people more likely to develop severe outcomes, including adults over 65, individuals with metabolic, lung, heart, neuromuscular or other long-term medical conditions, pregnant people and those with weakened immune systems.

H3N2 Subclade K Strain: Symptoms To Watch For

The symptoms linked to H3N2 mirror those seen with most influenza viruses and include:

• Fever
• Cough
• Runny nose
• Fatigue
• Muscle aches and chills

This strain may, however, push fevers higher and increase the chances of complications.

Will the New Flu Strain Make for a More Severe Flu Season?

It remains unclear how flu activity will evolve in the United States, and specialists say delays in reliable information have made it trickier to monitor patterns. During the 44-day government shutdown, the CDC paused all updates on respiratory illness. In the most recent “FluView” report for the week ending Nov. 15, national flu activity stayed low, though numbers are climbing, particularly in children. Test positivity and hospital admissions are also going up.

What To Know About The Flu Vaccine?

The CDC advises that everyone aged 6 months and older, with very few exceptions, should get their flu shot.

Still, despite this guidance, fewer people seem to be getting vaccinated each year. CDC figures show that flu vaccine distribution has steadily fallen since the 2021–22 season.

Is the Flu Shot Effective Against the New Strain?

Scientists select the strains for each year’s vaccine based on the viruses circulating globally early in the year, Hopkins explains. The 2025–2026 vaccine includes H1N1, H3N2 and influenza B.

Because the mutated subclade K appeared too late in the cycle, researchers could not adjust this season’s formula. It is not an exact match for the chosen H3N2 strain, but experts stress that the vaccine will still provide valuable protection during the season.

A flu shot does not always stop infection, but it does lower the chances of developing serious illness, needing hospital care or facing life-threatening complications. “The goal of vaccines is to reduce the severity of illness, and reduce the disease impact on our population,” Hopkins says.

This year’s vaccine is also expected to be a strong fit for the H1N1 and influenza B strains that are circulating, Hopkins adds. “You’ll get the protection against two other strains of flu, even if H3N2 isn’t optimal,” Pekosz notes.

As flu activity intensifies, getting vaccinated remains one of the simplest ways to build protection, even against the mutated strain, as doctors continue to underline.